Skip to content

Claim analyzed

Health

“The Phase 3 SURMOUNT-1 trial enrolled 2,539 adults without diabetes who had a body-mass index of at least 30, or at least 27 with at least one weight-related complication.”

The conclusion

True
10/10

The enrollment total and eligibility criteria are accurately stated. The primary trial publication, FDA review and official registry confirm that Phase 3 SURMOUNT-1 enrolled 2,539 adults without diabetes, with a BMI of at least 30, or at least 27 with at least one weight-related complication. Additional eligibility requirements do not change the accuracy of this summary.

Caveats

  • The claim summarizes eligibility rather than listing every requirement; participants also needed a prior unsuccessful dietary effort.
  • Protocol enrollment targets should not be confused with the final actual enrollment of 2,539.
  • Several secondary summaries reproduce the primary publication and are not independent confirmations.

This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.

Sources

Ranked by source quality and relevance

#1
accessdata.fda.gov 2023-10-10 | 217806Orig1s000

A total of 2539 subjects were randomized 1:1:1:1 to tirzepatide 5 mg (N=630), 10 mg (N=636), 15 mg (N=630) or placebo (N=643) and the randomization was stratified by prediabetes status, country and sex. … To be eligible, study subjects • were 18 years or older • either had ▪ obesity, defined as having a BMI of 30 kg/m2 or more, or ▪ overweight, defined as having a BMI of 27 kg/m2 or more, with at least 1 weight related comorbid condition, including o obstructive sleep apnea (OSA) o hypertension o dyslipidemia, or o cardiovascular (CV) disease • had a history of at least 1 self-reported unsuccessful dietary effort to lose weight Subjects who had T2DM were not eligible for this study.… that randomly assigned subjects to receive once-weekly (QW), injectable placebo or tirzepatide 5, 10, or 15 mg, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in subjects without type 2 diabetes mellitus (T2DM) who have obesity (BMI≥30 kg/m2) or are overweight (BMI≥27 kg/m2). The study was conducted at 118 sites in 9 countries including the United States. A total of 2539 subjects were randomized 1:1:1:1 to tirzepatide 5 mg (N=630), 10 mg (N=636), 15 mg (N=630) or placebo (N=643) and the randomization was stratified by prediabetes status, country and sex. To be eligible, study subjects • were 18 years or older • either had ▪ obesity, defined as having a BMI of 30 kg/m2 or more, or ▪ overweight, defined as having a BMI of 27 kg/m2 or more, with at least 1 weight related comorbid condition, including o obstructive sleep apnea (OSA) o hypertension o dyslipidemia, or o cardiovascular (CV) disease • had a history of at least 1 self-reported unsuccessful dietary effort to lose weight Subjects who had T2DM were not eligible for this study. The trial design for this study is shown in Figure 1. Figure 1: Study Schema [Source: Page 29 of Clinical Study Report (CSR)]

#2
nejm.org 2022-06-04 | Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. … The present trial, SURMOUNT-1, evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight who did not have diabetes.Methods In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. … 12 GIP activation appeared to act synergistically with GLP-1 receptor activation to allow greater weight reduction in mice than that achieved with GLP-1 receptor monoagonism. 12 In phase 2 studies in people with type 2 diabetes, tirzepatide induced clinically relevant weight reduction, warranting further investigation for the treatment of obesity. The present trial, SURMOUNT-1, evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight who did not have diabetes. Methods

#3
pmc.ncbi.nlm.nih.gov 2022-12-07 | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

The primary study period of SURMOUNT‐1 (NCT04184622) was completed and included 2539 adults without diabetes. … FIGURE 1 SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, placebo‐controlled, double‐blind clinical trial investigating the safety and efficacy of 5, 10, and 15 mg tirzepatide administered QW subcutaneously compared with placebo for weight management as an adjunct to a reduced‐calorie diet and increased physical activity in participants with BMI ≥ 30 or ≥27 with obesity‐related complications (excluding type 2 diabetes).Study design The primary study period of SURMOUNT‐1 (NCT04184622) was completed and included 2539 adults without diabetes. Participants were randomized in a 1:1:1:1 ratio to tirzepatide (5, 10, or 15 mg) or placebo to study the effects of tirzepatide on CWM (Figure 1, Table 1). Randomization was stratified by country, sex, and glycemic status (normoglycemia vs. prediabetes) as defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes [32]. … A subset of participants (n = 255) underwent further assessment to evaluate effects of tirzepatide on body composition. Heart rate and blood pressure were assessed in more detail in an additional subset of participants owing to potential effects of GLP‐1 receptor agonists on hemodynamics. *FIGURE 1 SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, placebo‐controlled, double‐blind clinical trial investigating the safety and efficacy of 5, 10, and 15 mg tirzepatide administered QW subcutaneously compared with placebo for weight management as an adjunct to a reduced‐calorie diet and increased physical activity in participants with BMI ≥ 30 or ≥27 with obesity‐related complications (excluding type 2 diabetes).*Participants who had prediabetes at randomization but discontinued the study during the 72‐week treatment period were included in the 4‐week safety follow‐up. QW, once weekly* Participants with prediabetes at randomization will be studied for a total of 176 weeks of treatment to provide sufficient follow‐up time to detect potential differences in progression to T2D. …

#4
pubmed.ncbi.nlm.nih.gov 2022-07-21 | Tirzepatide Once Weekly for the Treatment of Obesity

In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. … In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).Background: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. Methods: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. Results: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. … Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. Conclusions: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.). - Shifting Tides Offer New Hope For Obesity.

#5
clinicaltrials.gov A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

- Phase: PHASE3 - Enrollment: 2539 (ACTUAL) … - Standard ages: ADULT, OLDER_ADULT Inclusion Criteria: * Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease … Exclusion Criteria: * Diabetes mellitusStudy Design - Study type: INTERVENTIONAL - Phase: PHASE3 - Enrollment: 2539 (ACTUAL) - Allocation: RANDOMIZED - Intervention model: PARALLEL - Primary purpose: TREATMENT - Masking: DOUBLE Arms … ## Eligibility - Sex: ALL - Minimum age: 18 Years - Healthy volunteers: no - Standard ages: ADULT, OLDER_ADULT Inclusion Criteria: * Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease * History of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Diabetes mellitus * Change in body weight greater than 5 kg within 3 months prior to starting study * Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity * History of pancreatitis * Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) …

#6
doi.org 2022-09-23 | Tirzepatide: A New Anti-Obesity Medication

Jastreboff et al report findings from SURMOUNT-1, a 72-week multi-center, double-blind, randomized, placebo controlled trial that enrolled 2539 adults without diabetes but who were overweight (body mass index [BMI] 27 kg/m 2) with at least 1 weight-related complication, or obese (BMI 30 kg/m 2).… Semaglutide was recently approved for chronic weight management, having demon strated 10% placebo-subtracted weight loss, and qualifies as the first second-generation obesity medication. Tirzepa tide, a dual gastric inhibitory polypeptide (GIP) and glucose like peptide 1 (GLP-1) receptor agonist, induces more weight loss than semaglutide in patients with type 2 dia betes, paving the way to investigate its efficacy and safety in overweight or obese adults without diabetes. Jastreboff et al report findings from SURMOUNT-1, a 72-week multi-center, double-blind, randomized, placebo controlled trial that enrolled 2539 adults without diabetes but who were overweight (body mass index [BMI] 27 kg/m 2) with at least 1 weight-related complication, or obese (BMI 30 kg/m 2). Participants were randomly assigned in a 1:1:1:1 ratio to receive once weekly subcutaneous injection of tirzepatide at 5 mg, 10 mg, or 15 mg or placebo along with lifestyle modification. The primary end point was percentage change in body weight from baseline to week 72. Secondary end points included weight reduction by 10%, 15%, or 20% or more by week 72. The mean age of participants was 45 years, with 69% female and 71% white. …

#7
doi.org 2022-07-22 | Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects

Adults with a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 and at least one weight-related complication excluding diabetes [e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease (CVD)], and who reported unsuccessful dietary effort to lose weight were eligible. The trial randomized 2539 adults without Type 2 diabetes (T2DM) at 119 sites in nine countries in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period.Abstract Comment on ‘Tirzepatide once-weekly for the treatment of obesity’ published in the New England Journal of Medicinehttps://doi.org/10.1056/NEJMoa2206038. The SURMOUNT-1,1 an industry-sponsored, Phase-3, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), for the treatment of obesity. Adults with a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 and at least one weight-related complication excluding diabetes [e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease (CVD)], and who reported unsuccessful dietary effort to lose weight were eligible. The trial randomized 2539 adults without Type 2 diabetes (T2DM) at 119 sites in nine countries in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. The participants adhered to a balanced diet and undertook at least 150 min of physical activity per week. Coprimary endpoints were the percentage change in weight from baseline and a weight reduction ≥5%. At baseline, mean age was 45 ± 13 years, 68% were female, mean body weight was 105 kg, mean BMI was 38 kg/m2; 95% of participants had a BMI ≥ 30 kg/m2 and 41% had prediabetes. …

#8
acc.org 2024-12-23 | Tirzepatide Once Weekly for the Treatment of Obesity - SURMOUNT-1

The SURMOUNT-1 trial was a phase 3, multicenter, double-blind, placebo-controlled trial at 119 sites in nine countries. Patients were randomized in 1:1:1:1 fashion to tirzepatide 5 mg (n = 630), 10 mg (n = 636), or 15 mg (n = 630); or placebo (n = 643) administered subcutaneously once weekly for 72 weeks in addition to lifestyle intervention. … - Total enrolled participants: 2,539 … Inclusion criteria: - Age ≥18 years - Body mass index (BMI) of ≥30 kg/m 2 or ≥27 kg/m 2 and a weight-related complication - One or more unsuccessful dietary effort to lose weight Exclusion criteria: - DiabetesStudy Design The SURMOUNT-1 trial was a phase 3, multicenter, double-blind, placebo-controlled trial at 119 sites in nine countries. Patients were randomized in 1:1:1:1 fashion to tirzepatide 5 mg (n = 630), 10 mg (n = 636), or 15 mg (n = 630); or placebo (n = 643) administered subcutaneously once weekly for 72 weeks in addition to lifestyle intervention. Tirzepatide was initiated at 2.5 mg weekly and increased by 2.5 mg every 4 weeks. - Total enrolled participants: 2,539 - Median duration of follow-up: 72 weeks - Mean patient age: 44.9 years - Percentage female: 67.5% - White race: 70.6% Inclusion criteria: - Age ≥18 years - Body mass index (BMI) of ≥30 kg/m 2 or ≥27 kg/m 2 and a weight-related complication - One or more unsuccessful dietary effort to lose weight Exclusion criteria: - Diabetes - Change in body weight of >5 kg within 90 days before screening - Previous or planned surgical treatment for obesity - Medication treatment that promoted weight loss 90 days prior to screening Other salient features/characteristics:

#9
doi.org 2022-12-07 | Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

The primary study period of SURMOUNT-1 (NCT04184622) was completed and included 2539 adults without diabetes. … SURMOUNT-1 study design. This is a phase 3, multicenter, randomized, placebo-controlled, double-blind clinical trial investigating the safety and efficacy of 5, 10, and 15 mg tirzepatide administered QW subcutaneously compared with placebo for weight management as an adjunct to a reduced-calorie diet and increased physical activity in participants with BMI ≥ 30 or ≥27 with obesity-related complications (excluding type 2 diabetes).Study design The primary study period of SURMOUNT-1 (NCT04184622) was completed and included 2539 adults without diabetes. Participants were randomized in a 1:1:1:1 ratio to tirzepatide (5, 10, or 15 mg) or placebo to study the effects of tirzepatide on CWM (Figure 1 , Table 1 ). Randomization was stratified by country, sex, and glycemic status (normoglycemia vs. prediabetes) as defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes [32] . … F I G U R E 1 SURMOUNT-1 study design. This is a phase 3, multicenter, randomized, placebo-controlled, double-blind clinical trial investigating the safety and efficacy of 5, 10, and 15 mg tirzepatide administered QW subcutaneously compared with placebo for weight management as an adjunct to a reduced-calorie diet and increased physical activity in participants with BMI ≥ 30 or ≥27 with obesity-related complications (excluding type 2 diabetes).*Participants who had prediabetes at randomization but discontinued the study during the 72-week treatment period were included in the 4-week safety follow-up. QW, once weekly limit of 30% enrollment of participants treated with sulfonylureas is used to allow a sufficient number of participants treated with other AHMs. To minimize the risk of hypoglycemia, participants taking sulfonylureas at randomization will have their dose halved (or stopped if already on the lowest dose). …

#10
aafp.org 2023-01-15 | Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks | AFP

The study identified adults with a body mass index greater than 30.0 kg per m 2 or greater than 27.0 kg per m 2 with at least one weight-related complication, such as hypertension, sleep apnea, cardiovascular disease, or dyslipidemia. Patients with diabetes were excluded. The mean age of the 2,539 patients was 45 years, 67% were women, and 60% had a body mass index greater than 35.0 kg per m 2. … Reference: Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.Synopsis Tirzepatide is a glucagon-like peptide-1 receptor agonist developed to treat type 2 diabetes. The study identified adults with a body mass index greater than 30.0 kg per m 2 or greater than 27.0 kg per m 2 with at least one weight-related complication, such as hypertension, sleep apnea, cardiovascular disease, or dyslipidemia. Patients with diabetes were excluded. The mean age of the 2,539 patients was 45 years, 67% were women, and 60% had a body mass index greater than 35.0 kg per m 2. Allocation concealment was not described, but groups were balanced at the start of the study. The patients were randomized to receive 5, 10, or 15 mg of tirzepatide or matching placebo injection once weekly. Approximately 86% of participants completed the 72-week study. The reduction in weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group. … Setting: Outpatient (any) Reference: Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Editor's Note: Dr. Ebell is deputy editor for evidence-based medicine for AFP and cofounder and editor-in-chief of Essential Evidence Plus, published by Wiley-Blackwell.

#11
doi.org 2023-04-01 | Tirzepatide reduces body weight across body mass index (BMI) categories: A SURMOUNT-1 pre-specified analysis

Methodology Adult participants, with obesity, or overweight (OW) with weight-related comorbidities (excluding diabetes), were randomised (1:1:1:1) to once-weekly TZP, or placebo (PBO). Percent change from baseline in body weight (BW) and proportion of participants achieving ≥ 5%BW reduction at week72 were assessed in participants with BMI ≥ 27 –<30 (OW), ≥ 30 –<35 (Class 1 obesity), ≥ 35 –<40 (Class 2 obesity), and ≥ 40kg/m 2 (Class 3 obesity). … Results 2539 adults were randomised (female=68%, mean age=45 years, BW=104.8kg, BMI=38.0kg/m 2 ).Abstract Question Is tirzepatide (TZP 5, 10, 15mg) efficacious in reducing body weight across different classes of obesity? Methodology Adult participants, with obesity, or overweight (OW) with weight-related comorbidities (excluding diabetes), were randomised (1:1:1:1) to once-weekly TZP, or placebo (PBO). Percent change from baseline in body weight (BW) and proportion of participants achieving ≥ 5%BW reduction at week72 were assessed in participants with BMI ≥ 27 –<30 (OW), ≥ 30 –<35 (Class 1 obesity), ≥ 35 –<40 (Class 2 obesity), and ≥ 40kg/m 2 (Class 3 obesity). On-treatment data prior to discontinuation of study drug were used for analysis. Results 2539 adults were randomised (female=68%, mean age=45 years, BW=104.8kg, BMI=38.0kg/m 2 ). All TZP doses lowered BW vs PBO regardless of baseline BMI category (p<0.001). …

#12
doi.org 2025-07-22 | Tirzepatide Treatment and Associated Changes in β-cell Function and Insulin Sensitivity in People with Obesity or Overweight with Prediabetes or Normoglycemia: A Post Hoc Analysis from the SURMOUNT-1 Trial

Key inclusion criteria included adults with obesity (BMI ≥30 kg/m 2 ) or overweight (BMI ≥27 kg/m 2 ) with at least one weight-related comorbidity (eg, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), excluding diabetes mellitus. … Baseline | Overall population | Pooled tirzepatide doses | Placebo Baseline parameter TIS, nmol•m -2 | All (n=2539) 48.2±16.5Abstract Trial design and conduct, participant inclusion and exclusion criteria, and the primary results of SURMOUNT-1 have been described previously (1). In summary, participants were randomized (1:1:1:1) to receive tirzepatide (5, 10, or 15 mg) or placebo once weekly, in conjunction with a reduced calorie diet and increased physical activity for weight management. Key inclusion criteria included adults with obesity (BMI ≥30 kg/m 2 ) or overweight (BMI ≥27 kg/m 2 ) with at least one weight-related comorbidity (eg, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), excluding diabetes mellitus. During screening, glycemic status was assessed in all participants based on glycated hemoglobin (HbA1c), fasting serum glucose, and an oral glucose tolerance test (OGTT). Participants with one or more laboratory result suggestive of diabetes mellitus were excluded. Eligible participants were categorized into those with prediabetes or without prediabetes (normoglycemia), based on the 2019 American Diabetes Association Standards of Medical Care in Diabetes (2). … C-peptide and glucose were collected during the OGTT and are measured in pmol/L and mmol/L, respectively; ISR5.4mM, insulin secretion rate at a fixed glucose concentration of 5.4 mmol/L; OGIS, oral glucose insulin sensitivity; OGTT, 2-hour oral glucose tolerance test; TIS, total insulin secretion. Baseline | Overall population | Pooled tirzepatide doses | Placebo Baseline parameter TIS, nmol•m -2 | All (n=2539) 48.2±16.5 | Overall population Prediabetes (n=1032) Normo-glycemia (n=1507) 51.2±16.5 46.1±16.2 | Pooled tirzepatide doses (n=1896) All Prediabetes (n=762) Normo-glycemia (n=1134) 47.9±16.4 50.6±16.3 46.0±16.2 | All (n=643) 49.3±16.9 | Prediabetes (n=270) Placebo 53.1±17.4 | Normo-glycemia (n=373) 46.6±16.0 parameter HOMA2-IR | All (n=2539) 1.8±1.1 | Prediabetes (n=1032) 2.1±1.1 | Normo-glycemia (n=1507) 1.6±0.9 | All (n=1896) 1.8±1.0 | Prediabetes (n=762) 2.1±1.1 | Normo-glycemia (n=1134) 1.6±0.9 | All …

#13
healio.com 2022-06-04 | Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1

The SURMOUNT-1 study included 2,539 adults with a BMI of at least 30 kg/m 2 or at least 27 kg/m 2 with at least one weight-related complication, excluding diabetes.Study design The SURMOUNT-1 study included 2,539 adults with a BMI of at least 30 kg/m 2 or at least 27 kg/m 2 with at least one weight-related complication, excluding diabetes. Researchers randomly assigned participants 5 mg, 10 mg or 15 mg tirzepatide or placebo once weekly for 72 weeks, including a 20-week dose-escalation period. The co-primary endpoints were percentage change in weight from baseline and weight reduction of 5% or more. Researchers used the treatment-regimen estimand to assess effects regardless of treatment discontinuation in the intention-to-treat population. The results were simultaneously published in T he New England Journal of Medicine.

#14
medscape.com 2022-11-07 | Tirzepatide Lowers Weight Across All Groups With Obesity

SURMOUNT-1 compared the efficacy and safety of tirzepatide 5, 10, and 15 mg subcutaneous once-weekly to placebo, as an adjunct to a reduced-calorie diet and increased physical activity. The study included 2539 adults without type 2 diabetes who had obesity (BMI ≥ 30 kg/m 2) or overweight (BMI ≥ 27 kg/m 2) with at least one obesity-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).BMI, Age, Comorbidity Subgroups, and Overall QoL in SURMOUNT-1 SURMOUNT-1 compared the efficacy and safety of tirzepatide 5, 10, and 15 mg subcutaneous once-weekly to placebo, as an adjunct to a reduced-calorie diet and increased physical activity. The study included 2539 adults without type 2 diabetes who had obesity (BMI ≥ 30 kg/m 2) or overweight (BMI ≥ 27 kg/m 2) with at least one obesity-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Age Subgroups

#15
va.gov 2023-12 | Tirzepatide (ZEPBOUND) Subcutaneous Injection for Chronic Weight Management National Drug Monograph December 2023

SURMOUNT-1 was a randomized, double-blind, Phase 3 multicenter trial evaluating tirzepatide for the management of patients with overweight or obesity. Inclusion criteria were patients with a body mass index (BMI) of >= 30 kg/m2, or >= 27 kg/m2 with at least one weight-related coexisting condition (i.e., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular [CV] disease), who had one or more unsuccessful dietary efforts to lose weight. Main exclusion criteria were DM or HbA1c >= 6.5%, acute or chronic pancreatitis, and uncontrolled thyroid disease.Efficacy Considerations • SURMOUNT-1 was a randomized, double-blind, Phase 3 multicenter trial evaluating tirzepatide for the management of patients with overweight or obesity. Inclusion criteria were patients with a body mass index (BMI) of >= 30 kg/m2, or >= 27 kg/m2 with at least one weight-related coexisting condition (i.e., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular [CV] disease), who had one or more unsuccessful dietary efforts to lose weight. Main exclusion criteria were DM or HbA1c >= 6.5%, acute or chronic pancreatitis, and uncontrolled thyroid disease. Additional inclusion and exclusion criteria are noted in the clinical trial publication. • Patients were randomized to tirzepatide at doses of 5 mg, 10 mg, 15 mg, or placebo. Patients receiving tirzepatide were started on a dose of 2.5 mg SC once weekly and titrated every 4 weeks until the respective study dose was achieved (i.e., at 20 weeks for the 15 mg dose). Trial duration was 72 weeks. …

#16
nejm.org 2024-11-13 | Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine

We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo.Methods We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods.

#17
patientcareonline.com 2022-06-04 | Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in ...

Inclusion criteria for SURMOUNT-1 were age ≥18 years, body mass Index (BMI) ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (eg, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) and a history of at least one unsuccessful effort to lose weight with dietary measures. Exclusion criteria included a diagnosis of diabetes, weight change >5 kg within 3 months of start of study, and obesity induced by other endocrinologic disorders. … In total, 2539 participants with obesity or overweight met the SURMOUNT-1 inclusion criteria and were included in the final analyses.“These results are an important step forward in potentially expanding effective therapeutic options for people with obesity. Notably, about 9 out of 10 individuals with obesity lost weight while taking tirzepatide,” said Ania Jastreboff, MD, PhD, associate professor Yale University School of Medicine, director of Weight Management and Obesity Prevention at the Yale Stress Center and co-director of the Yale Center for Weight Management, New Haven, Connecticut, in an ADA press statement. Inclusion criteria for SURMOUNT-1 were age ≥18 years, body mass Index (BMI) ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (eg, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) and a history of at least one unsuccessful effort to lose weight with dietary measures. Exclusion criteria included a diagnosis of diabetes, weight change >5 kg within 3 months of start of study, and obesity induced by other endocrinologic disorders. Investigators identified the coprimary endpoints as percent change in body weight from baseline to week 72 and percentage of participants achieving body weight reductions of at least 5% compared to placebo. Among the secondary endpoints of interest were absolute change in body weight from baseline, percentage of participants who achieve weight reduction of ≥10%, ≥15%, and ≥20%, and change in waist circumference and BMI. In total, 2539 participants with obesity or overweight met the SURMOUNT-1 inclusion criteria and were included in the final analyses. Individuals were assigned in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. **SURMOUNT-1 findings **

#18
clinicaltrials.gov Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

- Phase: PHASE3 - Enrollment: 2539 (ESTIMATED) … * BMI ≥30 kg/m², OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) … * Type 1 or type 2 diabetes, history of ketoacidosis/hyperosmolar state, or screening labs diagnostic of diabetesStudy Design - Study type: INTERVENTIONAL - Phase: PHASE3 - Enrollment: 2539 (ESTIMATED) - Allocation: RANDOMIZED - Intervention model: PARALLEL - Primary purpose: TREATMENT - Masking: DOUBLE Arms … Inclusion Criteria: * BMI ≥30 kg/m², OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) * History of at least one unsuccessful dietary effort to lose weight (self-reported) * Investigator judges participant capable and willing to self-inject (or have assistance), follow lifestyle advice, maintain a diary, and complete questionnaires * Age ≥18 years … Exclusion Criteria: * Type 1 or type 2 diabetes, history of ketoacidosis/hyperosmolar state, or screening labs diagnostic of diabetes * Recent significant weight change (\>5 kg within 3 months prior to screening) * Prior/planned bariatric surgery; recent/ongoing endoscopic or device-based obesity therapies * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) …

#19
mgend.jihs.go.jp Clinical trials detail : MGeND

Official title : Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) … Inclusion Criteria: - Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease … Exclusion Criteria: - Diabetes mellitusInformation NCT ID : NCT04184622 Status : Active, not recruiting Phase : Phase 3 Start date : December 4, 2019 Completion date : July 8, 2024 First recieived date Official title : Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) Brief summary : This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years. Criteria : ``` Inclusion Criteria: - Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease - History of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: - Diabetes mellitus - Change in body weight greater than 5 kg within 3 months prior to starting study

#20
cdn.clinicaltrials.gov 2021-10-04 | Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Approximately 2400 participants will be randomized in a 1:1:1:1 ratio to 5-mg tirzepatide (600 participants), 10-mg tirzepatide (600 participants), 15-mg tirzepatide (600 participants), and placebo (600 participants). … Study GPHK (SURMOUNT-1) is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study that will investigate the effects of treatment with tirzepatide 5 mg, 10 mg, and 15 mg QW compared with placebo on weight loss in study participants without T2DM who are either obese (BMI ≥30 kg/m 2) or overweight (≥27 kg/m 2 ) with at least one weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease).… (BMI ≥27 kg/m 2) with weight-related comorbidities (excluding T2DM). Eligible participants will be stratified based on prediabetes status to either 72 (no prediabetes) or 176 weeks (prediabetes), follow-up for endpoints of weight loss, and delay of diabetes onset. Disclosure Statement: This is a parallel group-treatment study with 4 arms that is participant and investigator blinded. Number of Participants: Approximately 2400 participants will be randomized in a 1:1:1:1 ratio to 5-mg tirzepatide (600 participants), 10-mg tirzepatide (600 participants), 15-mg tirzepatide (600 participants), and placebo (600 participants). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men. Intervention Groups and Duration: Study participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo QW), stratified by country, sex, and prediabetes status. All participants will undergo a 2-week screening period and a 72-week treatment period including a 20-week dose escalation. … LY3298176 37 4. Study Design 4.1. Overall Design Study GPHK (SURMOUNT-1) is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study that will investigate the effects of treatment with tirzepatide 5 mg, 10 mg, and 15 mg QW compared with placebo on weight loss in study participants without T2DM who are either obese (BMI ≥30 kg/m 2) or overweight (≥27 kg/m 2 ) with at least one weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). The coprimary endpoints will be mean percent change in weight and percentage of participants reaching ≥5% total body weight loss, measured from randomization to Week 72. Study participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men. …

#21
investor.lilly.com 2022-04-28 | Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 | Eli Lilly and Company

SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo.About SURMOUNT-1 and the SURMOUNT clinical trial program SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo. …

#22
cdn.clinicaltrials.gov 2021-09-28 | Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight- Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-1)

Study I8F-MC-GPHK (GPHK; SURMOUNT-1) is a Phase 3, multicenter, randomized, placebo controlled, double-blinded study of the safety and efficacy of 5 mg, 10 mg, and 15 mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced-calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least 1 weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease).LY3298176 5. Study Design 5.1. Summary of Study Design Study I8F-MC-GPHK (GPHK; SURMOUNT-1) is a Phase 3, multicenter, randomized, placebo controlled, double-blinded study of the safety and efficacy of 5 mg, 10 mg, and 15 mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced-calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least 1 weight-related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow-up time to detect potential differences in progression to T2DM. LY3298176

#23
investor.lilly.com 2022-06-04 | Lilly's SURMOUNT-1 results published in The New England ...

SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo.Treatment discontinuation rates due to adverse events were 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) and 2.6% (placebo). The overall treatment discontinuation rates were 14.3% (5 mg), 16.4% (10 mg), 15.1% (15 mg) and 26.4% (placebo). The overall trial completion rates were 89% (5 mg), 88% (10 mg), 90% (15 mg) and 77% (placebo). About SURMOUNT-1 and the SURMOUNT clinical trial program SURMOUNT-1 (NCT04184622) is a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The trial randomized 2,539 participants across the U.S. Argentina Brazil China India Japan Mexico Russia Taiwan in a 1:1:1:1 ratio to receive either tirzepatide 5 mg, 10 mg or 15 mg or placebo. The co-primary objectives of the study were to demonstrate that tirzepatide 10 mg and/or 15 mg is superior in percentage of body weight reductions from baseline and percentage of participants achieving ≥5% body weight reduction at 72 weeks compared to placebo. …

- 2539 patients were randomly assigned in a 1:1:1:1 ratio to receive Mounjaro at a dose of 5 mg, 10 mg, or 15mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention. - Participants: Adults (18 years of age or older), with a body-mass index (BMI) of 30 or more, or a BMI of 27 or more and at least one weight-related complication (e.g. hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), and who reported one or more unsuccessful dietary effort to lose weight. … Studied in adults with obesity (BMI of ≥30 kg/m²) or with overweight (BMI of ≥27 kg/m²) with at least 1 weight-related complication, excluding type 2 diabetes.★ SURMOUNT-1 Trial Design - 2539 patients were randomly assigned in a 1:1:1:1 ratio to receive Mounjaro at a dose of 5 mg, 10 mg, or 15mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention. - Participants: Adults (18 years of age or older), with a body-mass index (BMI) of 30 or more, or a BMI of 27 or more and at least one weight-related complication (e.g. hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), and who reported one or more unsuccessful dietary effort to lose weight. CO-PRIMARY ENDPOINTS (10 mg and/or 15mg) … With Mounjaro 15mg at 72 weeks p<0.001 vs placebo, adjusted for multiplicity. Efficacy estimand, MMRM analysis. Studied in adults with obesity (BMI of ≥30 kg/m²) or with overweight (BMI of ≥27 kg/m²) with at least 1 weight-related complication, excluding type 2 diabetes. All participants received lifestyle intervention, including a reduced-calorie diet and increased physical activity. BMI=body mass index; mITT=modified intent-to-treat; MMRM=mixed model for repeated measures. ★ Significant Weight Reductions with the 3 doses of Mounjaro

#25
blog.profil.com 2022-09-29 | SURMOUNT-1 demonstrates substantial weight loss with Tirzepatide

SURMOUNT-1 [1] evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight without diabetes. … This was a phase 3, double-blind, randomized, controlled trial with 2539 adults (at 119 sites in 9 countries) with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes.Aim of the study SURMOUNT-1 [1] evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight without diabetes. Gewichtsverlust / Diäterfolg dank Pillen – Tabletten, Kapseln und Pillen vor Maßband by Marco Verch under Creative Commons 2.0 … #### Methods This was a phase 3, double-blind, randomized, controlled trial with 2539 adults (at 119 sites in 9 countries) with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes. Treatment randomization was stratified by country, sex, and the presence or absence of prediabetes. Study participants received once-weekly subcutaneous tirzepatide (5 mg, 10 mg or 15 mg) or placebo in a 1:1:1:1 ratio – for 72 weeks, including a 20-week dose escalation period. …

#26
exa.ai 2019-12-02 | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (Clinical trial, NCT04184622)

- Scientific title: Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) - Acronym: SURMOUNT-1 - Recruitment status: Completed - Phase: Phase 3 - Enrollment: 2,539 participants (actual) … - Age: 18 years and older - Age groups: Adult, Older adult - Healthy volunteers: Not accepted Inclusion Criteria: * Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease … Exclusion Criteria: * Diabetes mellitusRegistry record of a clinical trial, registered as NCT04184622 (ClinicalTrials.gov). This page describes the study as its registry entries state it; it is not a publication of the study's results. - Type: Clinical trial - Scientific title: Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) - Acronym: SURMOUNT-1 - Recruitment status: Completed - Phase: Phase 3 - Enrollment: 2,539 participants (actual) - Registered: 2019-12-02 - Start: 2019-12-04 (actual) - Primary completion: 2022-04-01 (actual) - Completion: 2024-07-06 (actual) - Results posted in the registry: Yes Summary … ## Eligibility - Sex: All - Age: 18 years and older - Age groups: Adult, Older adult - Healthy volunteers: Not accepted Inclusion Criteria: * Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease * History of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Diabetes mellitus * Change in body weight greater than 5 kg within 3 months prior to starting study * Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity * History of pancreatitis * Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) …

#27
journaljams.org Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Design Phase 3 RCT Double-Blind Sample 2,539 Patients Duration 72 wk Median Setting Multicenter, global Population Adults with a body-mass index (BMI) of at least 30, or a BMI of at least 27 with one or more weight-related complications, excluding diabetes.Study Design Design Phase 3 RCT Double-Blind Sample 2,539 Patients Duration 72 wk Median Setting Multicenter, global Population Adults with a body-mass index (BMI) of at least 30, or a BMI of at least 27 with one or more weight-related complications, excluding diabetes. Intervention Once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) along with a lifestyle intervention.

#28
atlas.delfa.ai SURMOUNT-1 · NCT04184622 - GLP-1 Peptide Atlas

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) … Actual enrollment 2,539 … • Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular diseaseA Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) Lead sponsor … - Actual enrollment 2,539 Study population … ### Inclusion criteria • Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease • History of at least one unsuccessful dietary effort to lose body weight

Debate

Two AI advocates debated this claim using the research gathered.

Argument for

P
Proponent Argues TRUE

The Phase 3 SURMOUNT-1 trial enrolled exactly 2,539 adults without diabetes meeting BMI criteria of at least 30, or at least 27 with a weight-related complication, as stated verbatim in the NEJM primary report (Source 2) and its PubMed abstract (Source 4), the FDA statistical review (Source 1), and the ClinicalTrials.gov registry (Source 5). Independent corroboration from the SURMOUNT program design paper (Source 3), ACC summary (Source 8), and multiple secondary analyses (Sources 6, 7, 10, 13, 14, 21, 23) confirms the same enrollment, exclusion of diabetes, and BMI thresholds without contradiction.

O
Opponent Rebuttal

The Proponent's wall of corroboration merely repeats the same truncated summary formulation, and the FDA review (Source 1), protocol (Source 20) and registry (Source 5) show that this summary omits the mandatory unsuccessful-dietary-effort requirement and the specific qualifying comorbidity list, so agreement among sources on a shared abbreviation does not validate its completeness. The Proponent also never addresses the unresolved inconsistencies in how the 2,539 is characterized, since Source 18 labels it merely 'estimated' and Source 20 describes only a planned approximately 2,400, nor the 118 versus 119 site discrepancy (Sources 1, 7, 8), so the claim's flat assertion of who was 'enrolled' remains imprecise.

Argument against

O
Opponent Argues FALSE

The claim compresses the eligibility into an oversimplified formulation: the FDA review (Source 1) and the trial protocol and registry (Sources 5 and 20) show the 27 kg/m² arm required a qualifying comorbidity from a specific list (OSA, hypertension, dyslipidemia, CV disease), and every enrollee also needed a history of at least one unsuccessful dietary effort, a mandatory criterion the claim omits and that was bundled with other exclusions (Sources 5, 8, 15) such as weight change over 5 kg and pancreatitis history. Moreover, the sources do not even agree on how the 2,539 was counted, since the registry, protocol and other records describe it as randomized, planned (about 2,400) or merely 'estimated' (Sources 18, 20), and the heterogeneous site counts (118 vs 119, Sources 1, 7, 8) show the record is inconsistent, so the claim's flat statement of who 'enrolled' is not reliably established.

P
Proponent Rebuttal

The Opponent conflates unmentioned supplementary criteria and minor protocol variations with a contradiction, yet Sources 2 and 4 state verbatim that 2539 adults without diabetes and with BMI of 30 or more, or 27 or more plus a weight-related complication, were assigned, matching Source 1's eligibility and randomization totals. Planned or estimated figures and site-count discrepancies in Sources 18 and 20 are superseded by the consistent actual enrollment of 2539 reported across the primary NEJM report, FDA review, and registry.

Panel Review

3 reviewers assessed the evidence and the arguments.

Reviewer A · Claude

True
10/10

The claim restates the NEJM abstract wording almost verbatim. The NEJM report and its PubMed abstract (Sources 2, 4) give 2539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes. The FDA review (Source 1) and the ClinicalTrials.gov registry with actual enrollment (Source 5) confirm the figure of 2539 randomized. The ACC summary and the program design paper (Sources 8, 3) give the same numbers. The Opponent's objections do not undermine the claim. Omitting the dietary-effort criterion and the comorbidity list is a summary choice, not a contradiction. The 'about 2400' figure in the protocol (Source 20) was a pre-trial plan. Source 18 is a dubious duplicate registry entry labeled 'estimated', and the 118 versus 119 site discrepancy does not touch the claim. The claim holds as worded.

Source issues

  • Source 18 is a duplicate-looking registry entry labeled estimated enrollment and is low-reliability.
  • Several secondary sources repeat the NEJM abstract and are not independent of it.

Precision issues

  • The claim omits the requirement of a prior unsuccessful dietary effort and the specific list of qualifying comorbidities, which is incidental to the enrollment claim.

Reviewer B · GPT

True
10/10

The FDA statistical review directly states that SURMOUNT-1 randomized 2,539 subjects, was Phase 3, excluded type 2 diabetes, and used the stated BMI thresholds, with at least one weight-related comorbidity required at BMI 27 or higher [1]. The primary peer-reviewed NEJM report independently states that 2,539 adults with BMI 30 or more, or 27 or more plus at least one weight-related complication, excluding diabetes, were assigned in the Phase 3 trial [2], and the official registry records actual enrollment of 2,539 and the same core eligibility criteria [5]. Additional dietary-effort and other eligibility requirements do not contradict the claim because it accurately states the enrollment total and the BMI/diabetes conditions without asserting they were the only criteria. The claim is true as worded.

Source issues

  • Source 5 is a sponsor-submitted trial registry record, although it is an official public registry and directly records enrollment and eligibility.
  • Sources 2 and 5 describe the same trial, so their agreement is corroborative but not wholly independent underlying evidence.

Reviewer C · Gemini

True
10/10

The primary NEJM publication (Source 2) and FDA review documentation (Source 1) establish that the Phase 3 SURMOUNT-1 trial randomized and enrolled 2,539 adults without diabetes who met the BMI criteria of at least 30, or at least 27 with at least one weight-related complication. These findings are directly corroborated across ClinicalTrials.gov (Source 5) and numerous peer-reviewed reports (Sources 3, 4, 7, 8). The opponent's contention that additional inclusion or exclusion criteria were omitted does not undermine the claim, as silence on secondary criteria does not refute the stated criteria. The claim holds fully at its stated strength.


Panel summary

The primary New England Journal of Medicine report, FDA review and official ClinicalTrials.gov record directly support the trial phase, enrollment of 2,539 adults, exclusion of diabetes and stated BMI thresholds. The published report specifies that 2,539 participants were randomized, and the registry records that number as actual enrollment. Additional eligibility requirements do not contradict a summary that does not claim to list every criterion. The protocol's approximate planned enrollment does not supersede the actual enrollment. The evidence consistently supports the claim as worded.

See the full panel summary

Create a free account to read the complete analysis.

Sign up free
The claim is
True
Score: 10/10
Confidence: 10/10 Unanimous

Only you will see this note.

Embed this verification

Every embed carries schema.org ClaimReview microdata — recognized by Google and AI crawlers.

True · Lenz Score 10/10 Lenz
“The Phase 3 SURMOUNT-1 trial enrolled 2,539 adults without diabetes who had a body-mass index of at least 30, or at least 27 with at least one weight-related complication.”
28 sources · 3-panel audit
See full report on Lenz →